Pharmaceutical giant Grifols may move headquarters out of Barcelona
Although the company has “no plans” to leave Catalonia, if politics affects business it will have to take "necessary measures"
Although the company has “no plans” to leave Catalonia, if politics affects business it will have to take "necessary measures"
Catalan pharmaceutical multinational continues to add to its R&D+i portfolio on back of acquiring minority stake in US firm GigaGen at start of July
The Catalan Government will offer to host the European Medicines Agency’s headquarters, which is currently in London. The body, which is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU, is looking for a new location after ‘Brexit’ and the Generalitat will defend Catalonia’s “potential in the pharmaceutical and biomedical sector” for Catalonia to become the agency’s new home. Indeed, in the nineties the Catalan Government already presented a “very solid portfolio” to house the European Medicines Agency, which was ultimately located in London’s Canary Wharf financial district. According to sources interviewed by CNA, Catalonia is now “racing” with other countries which have also presented their candidacies, such as Sweden, Denmark and Italy.
The Catalan company Grífols announced on Tuesday that they have purchased 20% of Singulex, the American multinational life science product provider based in Alameda, California. The acquisition was made after signing a capital increase worth $50 million, according to a statement given by Singulex to the National Securities Market Commission (CNMV). Singulex, which is valued ‘pre-money’ at $200 million, works in the field of diagnostic technology, such as technology used for screening blood and plasma donations, which could be used in the future to ensure the safety of transfusions and other similar procedures. The acquisition will not only grant Grífols a place on the American company´s board, but will also give the Catalan company access to the worldwide licence for the use and commercialisation of Singulex technology.
Grifols, a global healthcare company based in Greater Barcelona, announced on Wednesday that it will acquire 45% of the California-based firm Alkahest for $37.5 million. The biopharmaceutical company headquartered in Redwood City (near San Francisco) was founded last year upon the work of Stanford University scientists, who proved that factors in the blood of young animals were able to restore mental capabilities in old animals. This discovery has triggered Grifols' interest, a world leader in blood-derivative products. The two partners will work together on the development of novel plasma-based products for the treatment of cognitive impairment associated with age and other diseases of the central nervous system, including Alzheimer´s.
During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.
A plasma fractionation plant installed in Clayton, North Carolina by the company Grífols was unveiled on Tuesday by the President of the Catalan Government, Artur Mas, along with the President and CEO of the pharmaceutical, Víctor Grífols, and the State Governor, Pat McCrory. The new plant is 14,400 square metres big, will create over 200 jobs and represents an investment of 260 million euros. Expected to be operational by 2015, it will the largest and one of the most advanced plasma fractionation plants in the world. Grífols already has 2,300 employees in the state of North Carolina and it is among the world's top pharmaceuticals within the blood-derivates market. A few weeks ago, Víctor Grífols gave his support to the Catalan President and the self-determination process, which he confirmed on Tuesday.
28 employers’ associations, chambers of commerce and business organisations have signed a manifesto that explicitly backs Catalonia's right to self-determination. They presented the initiative on Thursday, in a lighthouse on the Costa Brava. The document is based on a previous agreement reached among employers and business associations just from Girona Province (north-east), but now it has been shared with organisations from throughout Catalonia. Some media, mostly edited in Madrid and abroad, are portraying the business community as against the self-determination process, but there are many employers that are backing it, even among the larger companies. A few weeks ago, the President and co-owner of the pharmaceutical Grífols – which is one of the world leaders for blood-derivate products – backed the Catalan President and his efforts to organise a self-determination vote.
Víctor Grífols, the President and part owner of the Catalan pharmaceutical company Grífols – which is one of the world leaders for blood-derivate products – has advised the President of the Catalan Government, Artur Mas to "go ahead" and "do not flinch", indirectly referring to Catalonia's self-determination process. At a public event to unveil the enlargement of the multinational's campus in Parets del Vallès (Greater Barcelona), Víctor Grífols stated: "When an organization – whatever its nature – has a clear goal to reach, a clear idea of which is the direction to follow in the future, it does not have to fear criticism questioning its strategy or raison d’être". The pharmaceutical firm has built a new plasma fractioning plant, which cost €20 million and will hire 70 new workers.
The profits of Catalan pharmaceutical company Grífols in 2013 grew by 34.6% over the previous year, reaching €345.6 million, as reported by the multinational to the Spanish Stock Exchange Regulation Authority (CNMV). The turnover of the company, based in Greater Barcelona, amounted to €2.75 billion, representing a 4.6% increase on 2012 figures. The geographical expansion of the pharmaceutical company has helped mitigating the effects of volatility in currencies, especially between the euro and the dollar. The Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) grew by 9.6% compared to 2012 and stood at €864.6 million, driven by an increase in the sales of plasma proteins and the optimization of the expenses for raw materials and manufacturing.
The Catalan pharmaceutical company Grífols and Barcelona’s Alzheimer Treatment&Research Center of Fundació ACE – a family charity – have announced that they will run tests of a vaccine against this neurodegenerative illness from January 2014. It will target 365 Alzheimer’s patients at mild and moderate stages of the illness. The first investigation project that ACE’s centre will host is called Ambar. The 365 participants will be randomly divided into three treatment groups plus a fourth control group. The patients will come from 17 Spanish hospitals and 20 United States’ medical centres. From 1996, the ACE Foundation has evaluated more than 14,000 people, 47% of whom were diagnosed with Alzheimer’s. It has the largest bank of genetic data in Europe.
Catalan pharmaceutical company Grífols has purchased 21.3% of Belgian biotech company TiGenix for €12 million through the subscription of a capital increase. TiGenix is a leading company in the field of cell therapy. The agreement settled on the appointment of two Grífols Members on TiGenix’s Board and a preferential right to negotiate the development and commercialization of all TiGenix products, with the only exception of advanced-medicinal product ChondroCelect. Earlier this month, Grífols had already strengthened its therapeutic arsenal by buying part of the Diagnostics unit of Swiss multinational Novartis for $1,675 million.
The Catalan pharmaceutical company Grífols, based in Greater Barcelona, has bought part of the diagnostics unit of Swiss multinational Novartis for $1,675 million. Grífols has acquired products and ‘in vitro’ technology applied to diagnoses in the fields of blood transfusion and immunology, along with a production plant in California and offices in the US, Switzerland and Hong Kong. With the acquisition, the Grífols Diagnostic Division will represent $1 billion, 20% of the Catalan group’s total revenues. Grífols is the world’s third largest company in the production of blood-plasma derivatives. In the first half of 2013, Grífols registered a profit of €182.2 million, an increase of 36.9% on the same period of 2012.
The Catalan pharmaceutical company posted a net profit of €182.2 million between January and June 2013, which represents an increase of 36.9% on the same period of 2012. 92.1% of Grífols sales are made abroad and this figure has reached €1.27 billion, up from 6.2% on the first half of last year. Total turnover stood at €1.38 billion, a 4.9% increase. Furthermore, between April and June, the multinational based in Greater Barcelona obtained its highest ever quarterly sales in absolute terms, which reached €697.1 million and represented a 7.2% increase on the same period of 2012. Last year, Grífols bought out its main competitor in the US, Telecaris, which made the Catalan company one of the main pharmaceutical companies in North America, particularly in the blood-derivate products.
The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in 2012 and almost doubled its sales compared to the 2011 figures. The company’s net profit last year quadruples that of 2011. The good results are due to a significant reduction in debt levels and Grífols’ penetration into the United States market. Besides, this week it announced it bought for €37 million the 60% of Progenika Biopharma’s capital, a Basque biotechnology company specialised in the design of diagnostic tests.